ClinicalTrials.gg
CompletedNCT03789656Updated Feb 17, 2025Results posted

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

A Phase 2 interventional study of Paltusotine in Acromegaly, sponsored by Crinetics Pharmaceuticals Inc.. Completed at 26 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Crinetics Pharmaceuticals Inc. (part of Vertex Pharmaceuticals Incorporated) · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens.

02

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Acromegaly
  • ACROBAT
  • EDGE
  • Paltusotine
03

In context

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

This study's enrollment of 47 is close to the median of 43 across 115 interventional studies indexed under Acromegaly.

Browse Acromegaly studies →

Lead sponsor

Crinetics Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.

First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects 18 to 75 years of age
  2. Confirmed diagnosis of acromegaly with either a partial or complete response to protocol defined somatostatin analogue therapy regimens
  3. Females must be non-pregnant and non-lactating, and either surgically sterile, , or using effective method(s) of
  4. Willing to provide signed

Exclusion criteria

Exclusion Criteria:

  1. Treatment naïve acromegaly subjects
  2. Prior treatment with paltusotine
  3. Pituitary surgery within 6 months prior to Screening. Subjects receiving radiation therapy may be eligible with some restrictions.
  4. History or presence of except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years
  5. Use of any drug within the past 30 days or 5 half-lives, whichever is longer
  6. Positive test at Screening for , surface antigen (HBsAg) or antibody (HCV-Ab) or has a history of a positive result
  7. History of alcohol or substance abuse in the past 12 months
  8. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study
  9. Cardiovascular conditions or medications associated with prolonged or those which predispose subjects to heart rhythm abnormalities
  10. Subjects with symptomatic cholelithiasis
  11. Subjects with abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study
  12. Subjects taking octreotide LAR at a dose higher than 40 mg, or lanreotide depot at a dose higher than 120 mg, or pasireotide LAR at a dose higher than 60 mg
  13. Subjects who usually take octreotide LAR or lanreotide depot less frequently than every 4 weeks (e.g. every 6 weeks or 8 weeks)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Paltusotine

    Drug: Paltusotine

Interventions

  • Paltusotine, capsules, once daily by mouth

    Also known as: CRN00808

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level

    Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).

    Time frame: 13 Weeks

Secondary outcomes

  1. Proportion of Subjects With Their Last IGF-1 Measurement ≤ Upper Limit of Normal (ULN)

    The secondary endpoint was the proportion of participants who maintained IGF-1 response, defined as the last assessment before the EoT with IGF-1 ≤1.0× ULN meet responder criteria, in Group 3, 4, and 5 subjects only at W13/EoT

    Time frame: 13 Weeks

  2. Proportion of Subjects With Their Last IGF-1 Measurements ≤1.5×ULN

    Proportion of participants with IGF-1 ≤1.5× ULN at W13/EoT.

    Time frame: 13 Weeks

07

Results

Posted Feb 17, 2025

Participant flow

A total of 45 subjects were planned to be enrolled in the study. 47 subjects participated in the study.

Screening Period: up to 6 Weeks
Participant flow — Screening Period: up to 6 Weeks
MilestoneGroup 1Group 2Group 3Group 4Group 5
Started2510543
Completed2510543
Not completed00000
Treatment Period: up to 13 Weeks
Participant flow — Treatment Period: up to 13 Weeks
MilestoneGroup 1Group 2Group 3Group 4Group 5
Started2510543
Completed2310433
Not completed20110
Withdrew: Prohibited medication10010
Withdrew: Covid-19 lockdown00100
Withdrew: Unable to travel10000
Follow-up Period: up to 4 Weeks
Participant flow — Follow-up Period: up to 4 Weeks
MilestoneGroup 1Group 2Group 3Group 4Group 5
Started2310433
Completed2210433
Not completed10000
Withdrew: Withdrawal by subject10000

Outcome measures

PrimaryChange From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level

Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).

Time frame:
13 Weeks
Reported as:
Median · ng/mL x ULN
Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level
ng/mL x ULNGroup 1
Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level-0.034 (-0.107 to 1.07)
Statistical analysis
  • Group 1 · Wilcoxon Signed Rank test · p = 0.6285
SecondaryProportion of Subjects With Their Last IGF-1 Measurement ≤ Upper Limit of Normal (ULN)

The secondary endpoint was the proportion of participants who maintained IGF-1 response, defined as the last assessment before the EoT with IGF-1 ≤1.0× ULN meet responder criteria, in Group 3, 4, and 5 subjects only at W13/EoT

Time frame:
13 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Their Last IGF-1 Measurement ≤ Upper Limit of Normal (ULN)
ParticipantsGroup 3Group 4Group 5
Baseline543
W13/EoT (Response)211
W13/EoT (No Response)332
Statistical analysis
  • Group 3 vs Group 4 vs Group 5 · exact binomial test assuming the null pr · p = 0.3877Null proportion = 0.5
SecondaryProportion of Subjects With Their Last IGF-1 Measurements ≤1.5×ULN

Proportion of participants with IGF-1 ≤1.5× ULN at W13/EoT.

Time frame:
13 Weeks
Reported as:
Count of participants · Participants
Proportion of Subjects With Their Last IGF-1 Measurements ≤1.5×ULN
ParticipantsGroup 1Group 2Group 3Group 4Group 5
Baseline (Response)196542
W13/EoT (Response)204431
W13/EoT (No Response)56112
PrimaryChange From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level

Change from baseline in IGF-1 level at Week 13/End of Treatment (W13/EoT) in Group 1 subjects Efficacy Analysis Set (EAS).

Time frame:
13 Weeks
Reported as:
Median · ng/mL x ULN
Change From Baseline (Median of Screening Values) in Insulin-like Growth Factor-1 (IGF-1) Level
ng/mL x ULNGroup 1
Baseline1.335 (1.078 to 1.471)
Week 13 (Visit 14)/ End of Treatment1.343 (1.169 to 1.448)

Adverse events

Collected over Participants were monitored until the end of the 4-week follow-up period (up to 17 weeks total).. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose 5 mg0/2 (0%)0/2 (0%)0/2 (0%)
Dose 10 mg0/47 (0%)0/47 (0%)23/47 (48.9%)
Dose 20 mg0/43 (0%)1/43 (2.3%)24/43 (55.8%)
Dose 30 mg0/37 (0%)0/37 (0%)15/37 (40.5%)
Dose 40 mg0/32 (0%)0/32 (0%)19/32 (59.4%)
Most frequent serious events
Most frequent serious events
EventDose 5 mgDose 10 mgDose 20 mgDose 30 mgDose 40 mg
HeadacheNervous system disorders0/20/471/430/370/32
Most frequent other events
Showing 10 of 16
Most frequent other events
EventDose 5 mgDose 10 mgDose 20 mgDose 30 mgDose 40 mg
HeadacheNervous system disorders0/26/475/434/377/32
ArthralgiaMusculoskeletal and connective tissue disorders0/25/473/432/375/32
FatigueGeneral disorders0/25/474/433/374/32
ParesthesiaNervous system disorders0/23/475/432/373/32
HyperhidrosisSkin and subcutaneous tissue disorders0/25/474/430/372/32
DiarrheaGastrointestinal disorders0/24/472/431/370/32
Abdominal painGastrointestinal disorders0/24/471/430/370/32
Peripheral swellingGastrointestinal disorders0/23/472/431/372/32
Abdominal distensionGastrointestinal disorders0/23/470/430/370/32
DyspepsiaGastrointestinal disorders0/21/471/431/372/32

Baseline characteristics

Of the 47 participants who received CRN00808-03, 42 participants completed the trial, 4 participants withdrew from treatment period, and 1 participant withdrew consent during follow up. No participants withdrew due to adverse events.

Age, Categorical
Age, Categorical(Participants)Group 1Group 2Group 3Group 4Group 5Total
<=18 years000000
Between 18 and 65 years22843239
>=65 years321118
Age, Customized
Age, Customized(years)Group 1Group 2Group 3Group 4Group 5Total
Age, y, median (range)52.0 (31 to 71)52.5 (31 to 70)51.0 (43 to 69)56.0 (46 to 67)38.0 (35 to 66)51.0 (31 to 71)
Sex: Female, Male
Sex: Female, Male(Participants)Group 1Group 2Group 3Group 4Group 5Total
Female11733327
Male14321020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1Group 2Group 3Group 4Group 5Total
Hispanic or Latino4620113
Not Hispanic or Latino21434234
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1Group 2Group 3Group 4Group 5Total
White25554342
Asian010001
Black or African American020002
Other020002
Region of Enrollment
Region of Enrollment(participants)Group 1Group 2Group 3Group 4Group 5Total
United States310228
Germany010001
Greece500106
Hungary510006
Italy001001
Poland200002
Romania000112
Serbia300003
Slovakia100001
United Kingdom200002
Brazil4630013
New Zealand011002
Height
Height(centimeter)Group 1Group 2Group 3Group 4Group 5Total
Median173.95 (166.50 to 178.50)167.75 (160.00 to 173.00)173.00 (164.00 to 176.00)169.45 (168.45 to 179.65)157.50 (155.50 to 169.00)170.25 (165.00 to 176.10)
Weight
Weight(kilogram(s))Group 1Group 2Group 3Group 4Group 5Total
Median90.95 (76.05 to 103.60)84.95 (75.00 to 117.00)87.30 (79.70 to 88.20)107 (88.75 to 114.35)77.50 (59 to 82.40)87.15 (75.10 to 104.20)

5 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • UCLA Gonda Diabetes Center
    Los Angeles, California 90095, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan
    Ann Arbor, Michigan 48106, United States
  • OHSU Northwest Pituitary Center
    Portland, Oregon 97239, United States
  • Allegheny Endocrinology Associates
    Pittsburgh, Pennsylvania 15212, United States
  • CETI - Centro de Estudos em Terapias Inovadoras
    Curitiba, Brazil
  • Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ) Centro de Pesquisa em Neuroendocrinologia
    Rio De Janeiro, Brazil
  • CPQuali Pesquisa Clinica
    São Paulo, Brazil
  • LMU Clinic of University of Munich
    Munich, Germany
  • General Hospital of Athens "Evangelismos"
    Athens, Greece
  • General Hospital of Athens "Gennimatas"
    Athens, Greece
  • General Hospital of Athens "Laiko"
    Athens, Greece
  • General Hospital of Athens "Ippokratio"
    Thessaloníki, Greece
  • Military Health Center, Division of Endocrinology
    Budapest, Hungary
  • Semmelweis University Faculty of Medicine
    Budapest, Hungary
  • University of Pécs Medical School
    Pécs, Hungary
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, Italy
  • Waitemata District Health Board, North Shore Hospital
    Takapuna, New Zealand
  • Endocrine, Diabetes and Research Centre, Wellington Hospital
    Wellington, New Zealand
  • Clinic of Endocrinology Independent Public Health Care Centre University Hospital in Kracow
    Krakow, Poland
  • National Institute of Endocrinology "C. I. Parhon"
    Bucharest, Romania
  • Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases
    Belgrade, Serbia
  • University Hospital Bratislava
    Bratislava, Slovakia
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Aug 2020, 16 months.

Results were first posted in Feb 2025, 4 years 6 months after primary completion. A results delay was requested in Jul 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2018
First posted
Dec 28, 2018
StartActual
Mar 12, 2019
Primary completionActual
Aug 3, 2020
CompletionActual
Aug 31, 2020
Results delay requested
Jul 27, 2021
Results first posted
Feb 17, 2025
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03789656
Responsible party
Sponsor
First posted
Dec 28, 2018
Start date
Mar 12, 2019
Primary completion
Aug 3, 2020
Completion
Aug 31, 2020
Results posted
Feb 17, 2025
Last update
Feb 17, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paltusotine

Start the discussion